NATCO Pharma receives USFDA approval for Lenalidomide Capsules

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has announced the final approval of its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsules, 5mg, 10mg, 15mg, and 25mg strengths, from the U.S. Food and Drug Administration (FDA), and the tentative approval of the 2.5mg and 20mg strengths.

NATCO, along with its marketing partner Arrow International Limited (a U.S. affiliate of Teva Pharmaceutical Industries Ltd), previously settled the Paragraph IV litigation related to the product with Celgene (now part of Bristol-Myers Squibb), who sells the product under the brand-name REVLIMID®. NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.

*All brand names and trademarks are the property of their respective owners.

Shares of NATCO PHARMA LTD. was last trading in BSE at Rs.990.8 as compared to the previous close of Rs. 932.9. The total number of shares traded during the day was 139698 in over 6426 trades.

The stock hit an intraday high of Rs. 998 and intraday low of 935. The net turnover during the day was Rs. 135789370.

Source : Equity Bulls

Keywords